FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance

FibroBiologics, Inc.

Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.
The Panel will consider the company's plan to regain compliance with both the bid price and MVLS rules at a hearing.
FibroBiologics filed a proxy seeking shareholder approval for a reverse stock split (1:5 to 1:30) to address bid price deficiency.
Trading continues pending the Panel's decision; no assurance of an extension or successful compliance.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.